Molecular Diagnostic technologies offer the potential for moving from diagnostics to prognostics. In the post era of accomplishing the “Human Genome Project”, Molecular Diagnostics is becoming the legitimate future diagnostics in healthcare. The genomic discovery has fueled the diagnostics because every gene-based therapeutic might need an accompanying (molecular) diagnostic test. At approximately 30,000 genes for the human genome and with an estimated diagnostic significance of about 5%, the commercialization of 1,500 gene-based tests can be expected.
Infectious disease testing and blood banking applications, followed by pharmacogenetics, predisposition diagnostics and molecular cancer diagnostics applications acquired significant benefit from the advantages of the molecular technologies present such as, sensitivity, specificity and speed. Molecular Diagnostics has been extremely successful in the area of infectious diseases where viral and bacterial genotyping has made rapid progress. Similarly, cancer diagnostics through mutational analysis and gene expression profiling is the next major breakthrough area in clinical practice. Healthcare professionals require a large range and high efficacy of tests to undertake correct diagnosis.
Cross-benefits like instant diagnostic results, more targeted therapies and shorter hospitalization time constitute higher costs for molecular test in comparison to traditional analyses like microbiology today. But Molecular Diagnostics helps to abate cost for diagnosis, therapy and healthcare altogether in the middle-term.
For more information, visit http://www.mscc.in/Department.aspx
